디소피라미드 인산염

동물 종별 용량

용량은 면허 수의 전문가를 위한 임상 참고 자료입니다. 항상 최신 라벨과 개별 환자에 대해 확인하십시오.

투여 경로

금기

• Hypersensitivity to the drug
• 2nd or 3rd degree AV block (unless a pacemaker is inserted)
• Cardiogenic shock
• Severe uncompensated or poorly compensated cardiac failure
• Hypotension
• Glaucoma (closed-angle)
• Urinary retention
• Myasthenia gravis

이상반응

• Dry mouth, eyes, or nose
• Constipation
• Urinary hesitancy or retention
• Urinary frequency and urgency
• Edema
• Hypotension
• Dyspnea
• Syncope
• Conduction disturbances (e.g., AV block)
• Vomiting and diarrhea
• Intrahepatic cholestasis
• Hypoglycemia
• Fatigue and headache
• Muscle weakness and pain
• Prolonged QT interval (at 15 mg/kg q8h in dogs)
• Widened QRS complex (at doses >30 mg/kg in dogs)

약물 상호작용

• Anticholinergic drugs (atropine, glycopyrrolate) · Additive anticholinergic effects may be encountered.
• Cisapride · Additional prolongation of the QT interval.
• Macrolide antibiotics (erythromycin, clarithromycin) · Increased disopyramide levels; prolongation of QT interval may occur.
• Phenobarbital · May increase disopyramide's metabolism and reduce serum levels.
• Procainamide, Lidocaine · May be used concurrently, but widening of QRS and prolongation of QT interval may occur.
• Quinidine · May increase disopyramide levels; disopyramide may decrease quinidine levels.
• Rifampin · May increase disopyramide's metabolism and reduce serum levels.
• Verapamil · Because of additional negative inotropic effects, use of disopyramide within 48 hours of using verapamil is not recommended.
• Propranolol · May cause additive negative inotropic effects.

모니터링

• ECG (monitor for QT prolongation and QRS widening)
• Blood pressure
• Clinical signs of adverse effects (anticholinergic and cardiovascular)
• Liver function tests (if on chronic therapy)
• Serum drug levels (Therapeutic: 2-7 mcg/mL; Toxic: >9 mcg/mL)

과용량

**Clinical signs of toxicity**: Anticholinergic effects, apnea, loss of consciousness, hypotension, cardiac conduction disturbances and arrhythmias, widening of the QRS complex and QT interval, bradycardia, congestive heart failure, seizures, asystole, and death. **Treatment**: * Initially consists of prompt gastric emptying, activated charcoal, and cathartics. * Follow with vigorous symptomatic therapy using cardiac glycosides, vasopressors, sympathomimetics, diuretics, mechanically assisted respiration, and endocardial pacing if necessary. * Disopyramide can be removed with hemodialysis.